Loading...

Homepage-2

ABOUT SEEKYO

SEEKYO® is a privately-owned biotech company developing a Smart Chemotherapy, selective to tumors, safe for patients.

We are designing smart drugs that selectively target the microenvironment of solid tumors while sparing healthy tissues.

We help increasing cancer patient’s quality of life by providing efficient and selective treatments without adverse effects.

Loading

SCIENCE

Chemotherapy is one of the main therapeutic option for cancer patients.

However, most anticancer drugs used clinically (standard chemotherapy) lack any intrinsic selectivity, causing severe side effects as the result of their toxicity toward healthy tissues.

Selectivity is key to ensure the drugs only act on cancer cells, sparing all other tissues. At SEEKYO® we have developed a completely new approach, a double targeting of the Tumor Micro-Environment

We call it Smart chemotherapy

10

Millions deaths in the world due to cancer

4700

new cancer diagnoses each day around the world

43

% of all cancer diagnosed are solid tumors (lung, breast, prostate...)

36

% of death are due solid tumors cancers (lung, breast, prostate...)

THERAPEUTIC NEEDS

Oncology treatment without adverse effects
Selectivity towards cancer versus healthy tissues
Specific cancer hallmarks

With the aim of offering improved treatments to cancer patients, SEEKYO‘s therapeutic vectors are

01

HARMLESS

Transport of potent anticancer agents in an innocuous manner toward safe tissues
02

EFFICIENT

Efficient recognition of malignant specificities
03

SELECTIVE

Controlled release of the parent drug exclusively at the tumor site

COMPETITIVE ADVANTAGES

Strong in vivo results
Versatile linker technology
Target tumor microenvironnement

THERAPEUTIC VECTORS

Smart drug targeting solid tumors
Cytotoxicity activity triggered exclusively in malignant tissues
No adverse effect

MARKET OFFER

Strong growing market (>$14b)
Custom design solutions for partners
Innovative drug candidates

TECHNOLOGY

SEEKYO®’s unique technology comprises a molecular platform enabling the custom design of almost any type of therapeutic vector.

This versatile linker technology offers the possibility to design “on demand” the most appropriate targeting assembly in order to treat a given malignancy, based on its unique tumor-associated specificities.

SEEKYO®’s self-immolative linker can gather in a single molecular entity:

  • an anticancer agent
  • a targeting unit
  • an enzymatic trigger

 

 

Step 1. SKY 01 binds covalently to circulating albumin leading to the formation of the bioconjugate

Step 2. The bioconjugate accumulates in the tumor microenvironment where enzymatic activation triggers the release of the drug molecules.

Step 3. The drugs penetrate inside surrounding cancer cells to exert their anticancer activity.

The versatility of the technology allows:

DRUG DEVELOPMENT

The development of the next generation of
smart therapeutic vectors targeting the
microenvironment’s hallmarks

INDUSTRIAL COLLABORATION

In optimizing the efficacy of current
Antibody Drug Conjugates (ADC)

.

PIPELINE

MEDIA

Discover our latest news and publications

SCIENTIFIC ADVISORY BOARD

   Drug Discovery

Medicinal Chemistry

Preclinical Development

Clinical Pharmacology

Email

contact@seekyo-therapeutics.com

Address

TECHNOPOLE GRAND POITIERS
4 rue Carol Heitz, 86000 Poitiers | FR

from January 2021
Site CEI, 2 Avenue Galilée
86360 Chasseneuil-du-Poitou | FR